Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC
PACIFIC-R provides mature data on OS and rwPFS from a large, real-world cohort, supporting consolidation durvalumab as a standard of care in this setting.
Authors
- A.R. Filippi
- V.D. Haakensen
- J.K. Field
- S. Anand
- S. Siva
- T. Shcherbakova
- F. McDonald
- P. Garrido Lopez
- M. Moskovitz
- C. Chouaid
- I. Diaz Perez
- V. Gregorc
- P. Chander
- T.J.N. Hiltermann
- S. Peters
- P. Baas
- F. Mornex
- Y. Qiao
- M.C. Garassino
- N. Girard
- J. Bar
- R. Fietkau
- S. Kao
- D.C. Christoph
- B. Solomon
Institutions
- AstraZeneca (United Kingdom) (GB)
- Oslo University Hospital (NO)
- University Medical Center Groningen (NL)
- University of Liverpool (GB)
- The University of Melbourne (AU)
- University of Groningen (NL)
- Universidad de Alcalá (ES)
- Université de Versailles Saint-Quentin-en-Yvelines (FR)
- University of Pavia (IT)
- Sheba Medical Center (IL)
- Leiden University Medical Center (NL)
- Peter MacCallum Cancer Centre (AU)
- Rambam Health Care Campus (IL)
- Roy Castle Lung Cancer Foundation (GB)
- Centre Hospitalier Universitaire Vaudois (CH)
- University of Chicago (US)
- Universitätsklinikum Erlangen (DE)
- Chris O’Brien Lifehouse (AU)
- Oncode Institute (NL)
- Hôpital Lyon Sud (FR)
- Royal Marsden Hospital (GB)
- AstraZeneca (United States) (US)
- Candiolo Cancer Institute (IT)
- Policlinico San Matteo Fondazione (IT)
- Evangelisches Krankenhaus Königin Elisabeth Herzberge (DE)
- Hôpital Intercommunal de Créteil (FR)
- Hospital Universitario Ramón y Cajal (ES)
- Institut Curie (FR)
Publication Details
- Journal
- ESMO Open
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1016/j.esmoop.2026.106070
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- AstraZeneca
- Cancer Council Victoria